VM — Voyageur Pharmaceuticals Cashflow Statement
0.000.00%
- CA$17.05m
- CA$17.01m
- CA$0.01m
Annual cashflow statement for Voyageur Pharmaceuticals, fiscal year end - November 30th, CAD millions except per share, conversion factor applied.
2021 November 30th | 2022 November 30th | 2023 November 30th | 2024 November 30th | 2025 November 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -2.05 | -1.75 | -1.4 | -1.71 | -3.53 |
| Depreciation | |||||
| Non-Cash Items | 0.703 | 0.276 | 0.296 | 0.476 | 0.906 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -0.308 | -0.244 | 0.11 | 0.927 | -0.268 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -1.65 | -1.72 | -0.991 | -0.302 | -2.89 |
| Capital Expenditures | -0.432 | -0.283 | -0.175 | -0.166 | -0.27 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 0 | 0.009 | 0 | — | — |
| Sale of Fixed Assets | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -0.432 | -0.274 | -0.175 | -0.166 | -0.27 |
| Financing Cash Flow Items | -0.176 | 0.03 | -0.063 | 0.138 | -0.081 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 2.9 | 1.21 | 1.14 | 0.632 | 3.26 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 0.81 | -0.781 | -0.029 | 0.163 | 0.101 |